 |
|
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2022;28(4):841-850. Published online 2022 Sep 19 DOI: https://doi.org/10.3350/cmh.2022.0239
|
|
Citations to this article as recorded by
 Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024
Abraham Koshy
Journal of Clinical and Experimental Hepatology.2025; 15(1): 102406. CrossRef Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis
Katherine M. Cooper, Ami K. Patel, Christopher A. Zammitti, Ellen Murchie, Alessandro Colletta, Deepika Devuni
Journal of Clinical and Experimental Hepatology.2025; 15(2): 102427. CrossRef The Changing Demographics and Epidemiology of Hepatocellular Carcinoma
Rushabh Gujarathi, Jeremy A. Klein, Chih-Yi Liao, Anjana Pillai
Clinics in Liver Disease.2025; 29(1): 1. CrossRef Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Santiago Iturbe-Rey, Claudia Maccali, Marco Arrese, Patricia Aspichueta, Claudia P. Oliveira, Rui E. Castro, Ainhoa Lapitz, Laura Izquierdo-Sanchez, Luis Bujanda, Maria J. Perugorria, Jesus M. Banales, Pedro M. Rodrigues
Atherosclerosis.2025; 400: 119053. CrossRef The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review
Daniele Gorski Medeiros, Luis Fernando Ferreira, Jessica da Silva Lamp, Luis Henrique Telles da Rosa
European Journal of Gastroenterology & Hepatology.2025; 37(2): 129. CrossRef Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Soroor Owrangi, James M. Paik, Pegah Golabi, Leyla de Avila, Ryuki Hashida, Ariana Nader, Annette Paik, Linda Henry, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics.2025; 61(3): 433. CrossRef Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Jacob J Gries, Jeffrey V Lazarus, Paul N Brennan, Mohammad S Siddiqui, Giovanni Targher, Chim C Lang, Salim S Virani, Carl J Lavie, Scott Isaacs, Juan Pablo Arab, Kenneth Cusi, Chayakrit Krittanawong
The Lancet Gastroenterology & Hepatology.2025; 10(1): 82. CrossRef Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
Nicholas W.S. Chew, Anurag Mehta, Rachel Sze Jen Goh, Audrey Zhang, Yiming Chen, Bryan Chong, Han Shi Jocelyn Chew, Asim Shabbir, Adrian Brown, Georgios K. Dimitriadis, Daniel Q. Huang, Roger Foo, Carel W. le Roux, Gemma A. Figtree, Marat Fudim, Ambarish
Circulation.2025; 151(1): 98. CrossRef The evolving role of liver biopsy: Current applications and future prospects
Purva Gopal, Xiaobang Hu, Marie E. Robert, Xuchen Zhang
Hepatology Communications.2025;[Epub] CrossRef Associations of the Intake of Individual and Multiple Flavonoids with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States
Chen Wang, Mengchu Li, Jiali Zhang, Hongguang Li, Yue Li, Siyu Huang, Huilian Zhu, Zhaoyan Liu
Nutrients.2025; 17(2): 205. CrossRef Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
Gut and Liver.2025; 19(1): 116. CrossRef Comparison of Referral Rates and Costs Using Fibrosis-4 and Enhanced Liver Fibrosis (ELF) Testing Strategies for Initial Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population
Samrat Yeramaneni, Stephanie T Chang, Ramsey C Cheung, Donald B Chalfin, Kinpritma Sangha, H Roma Levy, Artem T Boltyenkov
The Journal of Applied Laboratory Medicine.2025;[Epub] CrossRef Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
Matheus Souza, Marcio J. M. Amaral, Luan C. V. Lima, Cristiane Alves Villela‐Nogueira
Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today
Václav Šmíd, Karel Dvořák
Vnitřní lékařství.2024; 70(1): E8. CrossRef Circulating fatty acids and risk of severe non-alcoholic fatty liver disease in the UK biobank: a prospective cohort of 116 223 individuals
Pan Zhuang, Yang Ao, Xiaohui Liu, Hao Ye, Haoyu Li, Xuzhi Wan, Yu Zhang, Jingjing Jiao
Food & Function.2024; 15(20): 10527. CrossRef The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
Ehsan Amini-Salehi, Soheil Hassanipour, Mohammad-Hossein Keivanlou, Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Azin Vakilpour, Farahnaz Joukar, Mohammad Hashemi, Nazila Sattari, Mohammadreza Javid, Fariborz Mansour-Ghanaei
Nutrition Reviews.2024; 82(6): 815. CrossRef A global action agenda for turning the tide on fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Quentin M. Anstee, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Grac
Hepatology.2024; 79(2): 502. CrossRef Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani
Annals of Hepatology.2024; 29(1): 101153. CrossRef Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone
Metabolism.2024; 151: 155721. CrossRef Reply
Jong Woo Hahn, Soeun Kim, Dong Keon Yon
Clinical Gastroenterology and Hepatology.2024; 22(4): 905. CrossRef Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan Gray
The American Journal of the Medical Sciences.2024; 367(2): 77. CrossRef Walking the VLDL tightrope in cardiometabolic diseases
Mindy Kim, Ze Zheng
Trends in Endocrinology & Metabolism.2024;[Epub] CrossRef Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease
Peng‐sheng Ting, Wei‐Ting Lin, Chiung‐Kuei Huang, Hui‐Yi Lin, Tung‐Sung Tseng, Po‐Hung Chen
Alcohol: Clinical and Experimental Research.2024; 48(1): 88. CrossRef Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald
The Lancet Gastroenterology & Hepatology.2024; 9(2): 159. CrossRef Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
Mislav Barisic-Jaman, Marko Milosevic, Viktoria Skurla, David Dohoczky, Josip Stojic, Petra Dinjar Kujundzic, Maja Cigrovski Berkovic, Ana Majic-Tengg, Ana Matijaca, Tomo Lucijanic, Mirjana Kardum-Pejic, Vlatka Pandzic Jaksic, Srecko Marusic, Ivica Grgure
Biomedicines.2024; 12(2): 323. CrossRef Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis
Reham Mohammed Dawood, Ghada Maher Salum, Mai Abd El-Meguid, Basma EL-sayed Fotouh
Journal of Interferon & Cytokine Research.2024; 44(3): 111. CrossRef Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
Chul-min Lee, Eileen L. Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun
Hepatology.2024; 79(6): 1393. CrossRef Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction
Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe
Molecules.2024; 29(3): 709. CrossRef Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
Xiaoyan Wu, Yuzhou Shen, Yufei Meng, Jinsi Chen, Yongchen Zhang, Sheng Zeng, Huihui Xu
Life Sciences.2024; 341: 122498. CrossRef Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China
Run Zhou, Binbin Zhang, Wei Zhang, Tingting Kong, Jie Fu, Jie Li, Junping Shi
BMJ Open.2024; 14(2): e078333. CrossRef Updated Insights into Probiotics and Hepatobiliary Diseases
Xiaoyu Xu, Cheng Zhang, Guoyi Tang, Ning Wang, Yibin Feng
Biomedicines.2024; 12(3): 515. CrossRef Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study
Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha
Liver International.2024; 44(6): 1316. CrossRef Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography
Harish Gopalakrishna, Gayatri B. Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman
European Journal of Gastroenterology & Hepatology.2024; 36(4): 476. CrossRef Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Avneet Singh, Adam Buckholz, Sonal Kumar, Carolyn Newberry
Nutrients.2024; 16(5): 658. CrossRef Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283. CrossRef Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression
Ignazio S Piras, Johanna K DiStefano
Life Science Alliance.2024; 7(6): e202302517. CrossRef Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 235. CrossRef In response to: Steatotic liver disease-know your enemies
Michael H. Le, Linda Henry, Mindie H. Nguyen
Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef The impact of county-level food access on the mortality and post-transplant survival among patients with steatotic liver disease
Yutaka Endo, Diamantis I. Tsilimigras, Mujtaba Khalil, Jason Yang, Selamawit Woldesenbet, Kazunari Sasaki, Ashley Limkemann, Austin Schenk, Timothy M. Pawlik
Surgery.2024; 176(1): 196. CrossRef Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Julieta Trinks, María F Mascardi, Adrián Gadano, Sebastián Marciano
World Journal of Gastroenterology.2024; 30(14): 1982. CrossRef Burden of liver disease in Brazil, 1996–2022: a retrospective descriptive study of the epidemiology and impact on public healthcare
João Sérgio Fonseca Guimarães, Jordana Almeida Mesquita, Thais Yuki Kimura, Ana Luíza Matos Oliveira, M. Fatima Leite, André Gustavo Oliveira
The Lancet Regional Health - Americas.2024; 33: 100731. CrossRef The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik
Clinical Gastroenterology and Hepatology.2024; 22(10): 1999. CrossRef Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Takahiro Kodama, Tetsuo Takehara
Seminars in Liver Disease.2024; 44(02): 147. CrossRef Association between biological aging and the risk of mortality in individuals with non-alcoholic fatty liver disease: A prospective cohort study
Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Xinyu Han, Tiejun Zhang
Archives of Gerontology and Geriatrics.2024; 124: 105477. CrossRef An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients
Aaron P. Thrift, Theresa H. Nguyen Wenker, Kyler Godwin, Maya Balakrishnan, Hao T. Duong, Rohit Loomba, Fasiha Kanwal, Hashem B. El-Serag
Digestive Diseases and Sciences.2024; 69(7): 2430. CrossRef Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease
Nikolaos Fragkou, Efthimia Vlachaki, Ioannis Goulis, Emmanouil Sinakos
World Journal of Hepatology.2024; 16(5): 671. CrossRef Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
Tahira Foyzun, Maddie Whiting, Kate K. Velasco, Jessie C. Jacobsen, Mark Connor, Natasha L. Grimsey
British Journal of Pharmacology.2024; 181(15): 2391. CrossRef Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease
Tianzhu Chen, Xiang Qin, Jianping Jiang, Beihui He
Frontiers in Nutrition.2024;[Epub] CrossRef A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, Seung Up Kim, Vincent Wai-Sun Wong, Luca Valenti, Myer Glickman, Jaime Ponce, Christos S. Mantzoros, Javier Crespo, Henning Gronbaek, Wah Yang, Mohammed Eslam, Robert J. Wong, Mariana Verdelho Machado, M
Hepatology International.2024; 18(4): 1178. CrossRef Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020
Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui
Preventive Medicine Reports.2024; 44: 102798. CrossRef Mapping the global research landscape on nonalcoholic fatty liver disease and insulin resistance: A visualization and bibliometric study
Sa'ed H Zyoud, Omar E Hegazi, Samer O Alalalmeh, Muna Shakhshir, Faris Abushamma, Shadi Khilfeh, Samah W Al-Jabi
World Journal of Hepatology.2024; 16(6): 951. CrossRef Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease
Jennie Cao, Andy Shon, Luke Yoon, Aya Kamaya, Justin R. Tse
European Radiology.2024; 34(12): 7622. CrossRef Persons with metabolic dysfunction‐associated steatotic liver disease are at increased risk of severe depression
Hanne Åström, Ying Shang, Hannes Hagström, Axel Wester
Liver International.2024; 44(10): 2551. CrossRef An examination of global research trends for exploring the associations between the gut microbiota and nonalcoholic fatty liver disease through bibliometric and visualization analysis
Sa’ed H. Zyoud, Samer O. Alalalmeh, Omar E. Hegazi, Muna Shakhshir, Faris Abushamma, Samah W. Al-Jabi
Gut Pathogens.2024;[Epub] CrossRef Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation
Danting Mao, Jianwei Guo, Kunli Yang, Fan Yang, Jiaojiao Peng, Xu Jia, Ziren Luo, Lu Liu, Enjie Yang, Rui Tang, Haitao Lan, Qian Zheng
Biochemical and Biophysical Research Communications.2024; 734: 150424. CrossRef Dysfunctional VLDL metabolism in MASLD
Urko M. Marigorta, Oscar Millet, Shelly C. Lu, José M. Mato
npj Metabolic Health and Disease.2024;[Epub] CrossRef A systematic review and meta-analysis of randomized controlled trials: effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD
Yalan Xiong, Xinyu Shi, Xinying Xiong, Shenyu Li, Hanhua Zhao, Hualing Song, Jianying Wang, Lei Zhang, Shengfu You, Guang Ji, Baocheng Liu, Na Wu
Food & Function.2024; 15(16): 8248. CrossRef Food inequity and insecurity and MASLD: burden, challenges, and interventions
Shira Zelber-Sagi, Patrizia Carrieri, Juan M. Pericàs, Dana Ivancovsky-Wajcman, Zobair M. Younossi, Jeffrey V. Lazarus
Nature Reviews Gastroenterology & Hepatology.2024; 21(10): 668. CrossRef A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD
Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab
Seminars in Liver Disease.2024; 44(03): 273. CrossRef Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
Kahei Au, Ming-Hua Zheng, Wei-Jei Lee, Omar M. Ghanem, Kamal Mahawar, Asim Shabbir, Carel W. le Roux, Giovanni Targher, Christopher D. Byrne, Yusuf Yilmaz, Luca Valenti, Giada Sebastiani, Sombat Treeprasertsuk, Hannah Xiaoyan Hui, Nasser Sakran, Manoel Ga
Current Obesity Reports.2024; 13(4): 818. CrossRef Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
Merve Cebi, Yusuf Yilmaz
Frontiers in Immunology.2024;[Epub] CrossRef Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Xianhua Mao, Xinrong Zhang, Leslie Kam, Nicholas Chien, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen
Gut.2024; 73(12): 2054. CrossRef Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches
Shifat-E Ferdous, Jessica M. Ferrell
International Journal of Molecular Sciences.2024; 25(16): 8731. CrossRef Novel insights into causal effects of maternal nonalcoholic fatty liver disease on adverse pregnancy outcomes: evidence from Human Genetics and Mendelian Randomization Study
Qiuyan Luo, Guoting Liu, Qiulan Li, Jinghong Lu, Wenjing Zheng, Yukui Huang, Cun Li
European Journal of Clinical Nutrition.2024; 78(12): 1041. CrossRef Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Ritin Mohindra, Saptarshi Bhattacharya, Ameya Joshi, ABM Kamrul-Hasan
Indian Journal of Endocrinology and Metabolism.2024; 28(4): 336. CrossRef Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients
Siqi Ding, Qing Hong, Yuanyue Yao, Minwen Gu, Jie Cui, Wenhui Li, Jian Zhang, Chengcheng Zhang, Jinchi Jiang, Yonghong Hu
Food & Function.2024; 15(19): 9954. CrossRef The Clínica Universidad de Navarra-Body Adiposity Estimator index is a reliable tool for screening metabolic dysfunction-associated steatotic liver disease: an analysis from a gender perspective
Chao Wang, Xin Huang, Shiming He, Maobin Kuang, Guobo Xie, Guotai Sheng, Yang Zou
Lipids in Health and Disease.2024;[Epub] CrossRef Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song
Hepatology International.2024;[Epub] CrossRef Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease
Karolina Rzeniewicz, Rohini Sharma
World Journal of Clinical Oncology.2024; 15(11): 1394. CrossRef Invited Commentary: Radiology at the Forefront in the Fight against Metabolic Dysfunction–associated Steatotic Liver Disease
Sudhakar K. Venkatesh
RadioGraphics.2024;[Epub] CrossRef Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park
Diagnostics.2024; 14(20): 2305. CrossRef Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
Rongtao Lai, Scott Barnett, Xinrong Zhang, Leslie Yeeman Kam, Ramsey Cheung, Qing Xie, Mindie H. Nguyen, Gilaad G. Kaplan
PLOS Medicine.2024; 21(10): e1004479. CrossRef DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim
Clinical and Molecular Hepatology.2024; 30(4): 824. CrossRef Modelo Wistar de doença hepática gordurosa não alcoólica: indução por fonte natural de colesterol
Maysa Ortolani Matera, Gabriel dos Santos, Maíza Pelissari Migliorini, Karyn Maria Wenglarek, Thais de Lima da Silva, Flávia Cristina Colmenero, Isabela Hess Justus, Bruna Karas, Marcelo de Oliveira Dreweck, Sérgio Ossamu Ioshii, Mario Claudio Soares Stur
Cuadernos de Educación y Desarrollo.2024; 16(11): e6263. CrossRef Machine-Learning Application for Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease Using Laboratory and Body Composition Indicators
Fatemeh Masaebi, Mehdi Azizmohammad Looha, Morteza Mohammadzadeh, Vida Pahlevani, Mojtaba Farjam, Farid Zayeri, Reza Homayounfar
Archives of Iranian Medicine.2024; 27(10): 551. CrossRef Coexisting metabolic dysfunction-associated steatotic liver disease exacerbates in-hospital outcomes in patients with heat stroke
Ping Zhang, Guo Tang, Hongguang Gao, Tianshan Zhang, Sha Yang, Tao Cheng, Rong Yao
Frontiers in Medicine.2024;[Epub] CrossRef Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040
Sikai Qiu, Jiangying Cai, Zhanpeng Yang, Xinyuan He, Zixuan Xing, Jian Zu, Enrui Xie, Linda Henry, Custis R. Chong, Esther M. John, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen
JAMA Network Open.2024; 7(11): e2445525. CrossRef Doença hepática gordurosa não alcoólica experimental induzida por dieta rica em colesterol
Maíza Pellissari Migliorini, Gabriel dos Santos, Maysa Ortolani Matera, Karyn Maria Wenglarek, Thais de Lima da Silva, Jaqueline Meert Parlow, Isabela Hess Justus, Flávia Cristina Colmenero, Marcelo de Oliveira Dreweck, Sérgio Ossamu Ioshii, Mário Cláudio
Cuadernos de Educación y Desarrollo.2024; 16(11): e6598. CrossRef Comparative analysis of NAFLD-related health videos on TikTok: a cross-language study in the USA and China
Hongyu Wu, Jialun Peng, Shengwei Li, Xiong Ding, Tao Zhong, Qilong Zhai, Changjie Du, Jiajun Yuan, Can Cai, Jinzheng Li
BMC Public Health.2024;[Epub] CrossRef Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)
Lucy C. Taylor, Gertrude Arthur, Marcella de Carvalho Cruz, David E. Stec, Olufunto O. Badmus
International Journal of Translational Medicine.2024; 4(4): 782. CrossRef Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608. CrossRef Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Min-Kyu Kang, Min-Cheol Kim
Medicina.2023; 59(2): 375. CrossRef The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
George Chen, Bubu Banini, Albert Do, Joseph K. Lim
Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease
Rongtao Lai, Mindie H. Nguyen
Clinical Gastroenterology and Hepatology.2023; 21(11): 2984. CrossRef The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Metabolites.2023; 13(5): 581. CrossRef The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women
Johanna K. DiStefano
Nutrients.2023; 15(12): 2670. CrossRef Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports.2023; 25(8): 151. CrossRef Cardiovascular outcomes among persons with HIV and nonalcoholic fatty liver disease
Sepiso K. Masenga, Lweendo Muchaili, Benson M. Hamooya
AIDS.2023; 37(8): 1329. CrossRef Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark
International Journal of Obesity.2023; 47(8): 677. CrossRef Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Amina Basha, Sarah C. May, Ryan M. Anderson, Niharika Samala, Raghavendra G. Mirmira
International Journal of Molecular Sciences.2023; 24(12): 9996. CrossRef Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
Ultrasonography.2023; 42(3): 421. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber-Sagi, Linda Henry, Lynn H. Gerber
Nature Reviews Gastroenterology & Hepatology.2023; 20(11): 708. CrossRef The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study
Matina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Stergios A. Polyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodorid
Metabolism.2023; 147: 155666. CrossRef Ca2+ signaling and the Hippo pathway: Intersections in cellular regulation
Samar Sayedyahossein, Louise Thines, David B. Sacks
Cellular Signalling.2023; 110: 110846. CrossRef The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study
Matina Kouvari, Sophia C. Mylonakis, Angeliki Katsarou, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Michail Kokkorakis, Ornella Verrastro, Giulia Angelini, Georgios Markakis, Mohammed Eslam, Jacob George, Georgios Papatheodoridis, Geltrude Ming
Diabetes Research and Clinical Practice.2023; 203: 110870. CrossRef Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Aleksander Krag, Maria Buti, Jeffrey V. Lazarus, Alina M. Allen, Jacqueline Bowman, Patrizia Burra, Giacomo Donnini, Ajay Duseja, Manal H. El-Sayed, Amalia Gastaldelli, Ben Hainsworth, Tom H. Karlsen, Michael Kessler, Marko Korenjak, Henry E. Mark, Jake P
Journal of Hepatology.2023; 79(5): 1076. CrossRef Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review
Fateme Ziamanesh, Mehdi Mohammadi, Sholeh Ebrahimpour, Ozra Tabatabaei-Malazy, Asieh Mosallanejad, Bagher Larijani
Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1083. CrossRef Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019
Jie Li, Qingzhi Wang, Wenjing Ni, Chuan Liu, Zhihui Li, Xiaolong Qi
Global Transitions.2023; 5: 160. CrossRef The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry
Nasser Alorfi, Ahmed Ashour
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3115. CrossRef Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?
Chrysi Koliaki, Maria Dalamaga, Stavros Liatis
Current Obesity Reports.2023; 12(4): 514. CrossRef Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama
International Journal of Molecular Sciences.2023; 24(20): 15473. CrossRef An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Timothy J. Kendall, Maria Jimenez-Ramos, Frances Turner, Prakash Ramachandran, Jessica Minnier, Michael D. McColgan, Masood Alam, Harriet Ellis, Donald R. Dunbar, Gabriele Kohnen, Prakash Konanahalli, Karin A. Oien, Lucia Bandiera, Filippo Menolascina, An
Nature Medicine.2023; 29(11): 2939. CrossRef Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis
Tingting Kong, Yunpeng Gu, Lei Sun, Run Zhou, Jie Li, Junping Shi
Endocrine Journal.2023; 70(10): 959. CrossRef Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
Hepatology.2023; 78(6): 1858. CrossRef The Impact and Burden of Dietary Sugars on the Liver
Helaina E. Huneault, Ana Ramirez Tovar, Cristian Sanchez-Torres, Jean A. Welsh, Miriam B. Vos
Hepatology Communications.2023;[Epub] CrossRef Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area †
Tanmoy Mondal, Coleman I. Smith, Christopher A. Loffredo, Ruth Quartey, Gemeyel Moses, Charles D. Howell, Brent Korba, Bernard Kwabi-Addo, Gail Nunlee-Bland, Leanna R. Rucker, Jheannelle Johnson, Somiranjan Ghosh
International Journal of Molecular Sciences.2023; 24(23): 16654. CrossRef Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States
Pedro Ochoa-Allemant, Jorge A. Marrero, Marina Serper
Hepatology Communications.2023;[Epub] CrossRef The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review
Manpreet Kaur, Shanmathi Murugesan, Sachpreet Singh, Katherine N Uy, Jasjeet Kaur, Navina Mann, Rajneet K Sekhon
Cureus.2023;[Epub] CrossRef International diet quality index and revised diet quality index relationship with non-alcoholic fatty liver disease: a case-control study
Narjes Najibi, Mitra Kazemi Jahromi, Farshad Teymoori, Hossein Farhadnejad, Ammar Salehi-Sahlabadi, Parvin Mirmiran
BMC Gastroenterology.2023;[Epub] CrossRef Developmental Programming: Impact of Prenatal Exposure to Bisphenol A on Senescence and Circadian Mediators in the Liver of Sheep
Giuliana Motta, Soundara Viveka Thangaraj, Vasantha Padmanabhan
Toxics.2023; 12(1): 15. CrossRef Nonalcoholic fatty liver disease: a review of physiology, treatments, and market outlook
Pammar Aryan
Advances in Tissue Engineering & Regenerative Medicine: Open Access.2023; 9(1): 42. CrossRef Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han
Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
|